Longeveron announces updated results from Elpis II Phase 2B trial of laromestrocel for HLHS

LGVN•2026-10-26

Longeveron announced updated results from its Elpis II Phase 2B clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome.

1. Trial update

Longeveron announced updated results from the Elpis II Phase 2B clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome.

Longeveron announces updated results from Elpis II Phase 2B trial of laromestrocel for HLHS

1. Trial update

Related News

NiSource Inc.: RBC cuts target price to $46 from $52

WEC Energy Group target price cut to $122 from $124

Verizon lifts annual forecasts, signs more than $2 billion AI infrastructure deal with AWS

PSEG: RBC cuts target price to $76 from $81

Quantum copper steals the show at LME Week